Fulcrum Therapeutics (FULC) announced that it has entered into a collaboration and license agreement with Sanofi (SNY) for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Under the collaboration and license agreement, Sanofi obtains exclusive commercialization rights for losmapimod outside of the U.S. Fulcrum will receive an upfront payment of $80M, and is eligible to receive $975M in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50. In addition, Fulcrum and Sanofi will equally share future global development costs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics (FULC) Q1 Earnings Cheat Sheet
- Fulcrum announces publication of results on Phase 2b trial of losmapimod
- Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer